Press Release


Eisai Satisfies All-Case Surveillance Condition for Approval of Anti-Cancer Agent Lenvima in Treatment of Thyroid Cancer
Dec 09, 2019 08:17 JST
Eisai Co., Ltd. has received a notification from Japan's Ministry of Health, Labour, and Welfare (MHLW) to the effect that the "all-case surveillance" special drug use-results survey condition required for approval of the orally available kinase inhibitor LENVIMA (lenvatinib) in treatment of thyroid cancer has been cleared.
More info..

Eisai to Present New Research on Eribulin (Halaven) at 42nd Annual San Antonio Breast Cancer Symposium
Dec 05, 2019 08:11 JST
The symposium will be held from December 10 through 14, 2019, in San Antonio, Texas in the United States.
More info..

Eisai to Present Latest Data on Alzheimer's Disease / Dementia Pipeline at 12th Clinical Trials on Alzheimer's Disease Conference
Dec 02, 2019 08:23 JST
BAN2401 is being jointly developed by Eisai and Biogen Inc. In addition, the simple blood diagnostics for AD are being jointly developing by Eisai and Sysmex Corporation.
More info..

Eisai: Additional Indication for Lenvima (Lenvatinib) for Differentiated Thyroid Cancer Accepted in China
Dec 02, 2019 08:08 JST
Eisai Co., Ltd. has announced that LENVIMA (generic name: lenvatinib), the orally available kinase inhibitor discovered by Eisai, has been accepted by the National Medical Products Administration of China for an application for the additional indication of differentiated thyroid cancer.
More info..

Eisai to Present Latest Data on Perampanel at the 73rd American Epilepsy Society Annual Meeting
Nov 26, 2019 08:37 JST
Eisai Co., Ltd. has announced that the latest data on its antiepileptic drug (AED) perampanel (product name: Fycompa) will be presented at the 73rd American Epilepsy Society Annual Meeting (AES 2019) to be held from December 6 to December 10, 2019 in Baltimore, Maryland in the United States.
More info..

Eisai's Equfina 50mg Tablets (Safinamide Mesilate) Launched in Japan
Nov 20, 2019 13:01 JST
Eisai Co., Ltd. announced today that it has launched the Equfina 50mg TABLETS for the indication of improvement of the wearing-off phenomenon in patients with Parkinson's disease under treatment with a drug containing levodopa in Japan.
More info..

Eisai Transfers Rights to Receive Royalties Outside of Japan for EZH2 Inhibitor Tazemetostat to Royalty Pharma
Nov 05, 2019 09:02 JST
Eisai Co., Ltd. announced today that it has entered into an agreement to transfer the rights to receive royalties on the sales outside of Japan for an investigational anti-cancer agent tazemetostat (generic name) to Royalty Pharma.
More info..

Biogen Plans Regulatory Filing for Aducanumab in Alzheimer's Disease Based on New Analysis of Larger Dataset from Phase 3 Studies
Oct 23, 2019 10:13 JST
Biogen and Eisai, Co., Ltd. has announced that, after consulting with the U.S. Food and Drug Administration (FDA), Biogen plans to pursue regulatory approval for aducanumab, an investigational treatment for early Alzheimer's disease (AD).
More info..

Eisai's New Drug Approval for Fycompa for Adjunctive Treatment of Partial Onset Seizures in China
Oct 15, 2019 20:24 JST
Eisai Co., Ltd. has announced that Eisai received a New Drug Approval for its in-house discovered and developed antiepileptic drug (AED) Fycompa (perampanel) from the China National Medical Products Administration (NMPA) for use in an adjunctive treatment of partial onset seizures (with or without secondarily generalized seizures) in epilepsy patients 12 years of age and older.
More info..

Eisai: Final Study Results Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Treatment in Advanced Endometrial Cancer Presented at ESMO 2019 Congress
Oct 01, 2019 10:46 JST
The findings were presented in a proffered paper presentation at the European Society for Medical Oncology (ESMO) 2019 Congress (Abstract #994O).
More info..

Eisai and Nichi-Iko Enter into Collaboration Agreement for Generic Pharmaceutical Business in China
Sep 30, 2019 11:06 JST
Eisai Co., Ltd. and Nichi-Iko Pharmaceutical have entered into a comprehensive collaboration agreement for the generic pharmaceutical business in China.
More info..

Eisai and Tokio Marine Nichido Enter Into Business Alliance for Co-Existence and Prevention of Dementia
Sep 26, 2019 13:21 JST
Eisai Co., Ltd. and Tokio Marine & Nichido Fire Insurance Co., Ltd. announced today that the companies have entered into a business alliance agreement for co-existence and prevention of dementia.
More info..

Eisai and Fronteo to Launch Coroban Tumbling and Falling Prediction System for Inpatients
Sep 26, 2019 13:08 JST
Eisai Co., Ltd. and FRONTEO, Inc. announced today that they have launched the tumbling and falling prediction system Coroban to medical institutions in Japan on September 26, 2019.
More info..

Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO 2019 Congress
Sep 24, 2019 09:01 JST
Eisai Co., Ltd. announced today that a series of abstracts will be presented during the European Society for Medical Oncology (ESMO) 2019 Congress taking place in Barcelona, Spain, from September 27 to October 1, 2019.
More info..

Eisai and Meiji Announce Parkinson's Disease Treatment Equfina Tablets (Safinamide Mesilate) Approved In Japan
Sep 20, 2019 15:13 JST
In Japan, Meiji holds the manufacturing and marketing approval for safinamide, and Eisai exclusively sells the safinamide.
More info..

Eisai's Promotion and Distribution Agreement with Mylan India for Eribulin Second Brand in India
Sep 20, 2019 08:40 JST
Eisai Co., Ltd. has announced that Eisai's subsidiary Eisai Pharmaceuticals India Pvt. Ltd. and Mylan N. V. subsidiary Mylan India have entered into a license agreement to promote and distribute the second brand TECERIS for the anticancer agent eribulin mesylate (eribulin) in India.
More info..

Eisai to Present Latest Data on Lemborexant at World Sleep Congress
Sep 19, 2019 19:06 JST
Eisai Co., Ltd. has announced that latest data on lemborexant, an investigational sleep-wake regulation agent being studied for the treatment of sleep-wake disorders, including insomnia and Irregular Sleep-Wake Rhythm Disorder (ISWRD) associated with Alzheimer's disease/dementia will be presented at World Sleep Congress (World Sleep 2019), from September 20 to 25 in Vancouver, Canada.
More info..

Eisai Selected for Membership in Dow Jones Sustainability Asia Pacific Index 2019
Sep 18, 2019 20:40 JST
Eisai Co., Ltd. has been selected for a membership in the Dow Jones Sustainability Asia Pacific Index (DJSI Asia Pacific), the Asia Pacific version of the Dow Jones Sustainability Indices (DJSI), which are a family of premier global indices for socially responsible investment (SRI).
More info..

FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Treatment for Patients with Certain Types of Endometrial Carcinoma
Sep 18, 2019 13:58 JST
Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) approved the combination of LENVIMA, the orally available kinase inhibitor discovered by Eisai, plus KEYTRUDA, Merck & Co., Inc., Kenilworth, N.J., U.S.A.'s anti-PD-1 therapy.
More info..

Eisai Receives IIA Japan Chairman's Award of Institute of Internal Auditors - Japan
Sep 17, 2019 15:42 JST
Eisai Co., Ltd. has announced that it received the 33rd "IIA Japan Chairman's Award" of the Institute of Internal Auditors - Japan.
More info..

Eisai and Biogen to Discontinue Phase III Clinical Studies of Bace Inhibitor Elenbecestat in Early Alzheimer's Disease
Sep 13, 2019 17:43 JST
Eisai Co., Ltd and Biogen Inc. today announced the decision to discontinue the Phase III clinical studies (MISSION AD1, AD2) on the investigational oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat (development code: E2609) in patients with early Alzheimer's disease (AD).
More info..

Eisai to Launch New "Etak Antimicrobial Wet Wipes" With One Week Lasting Antimicrobial Action
Aug 29, 2019 10:46 JST
Eisai Co., Ltd. will launch ETAK( Antimicrobial Wet Wipes (classified as miscellaneous goods) containing long-acting antimicrobial agent ETAK on August 29, 2019 at pharmacies and drugstores countrywide.
More info..

Eisai Enters Into Business Alliance With Cogstate for Exclusive Development and Commercialization of a Digital Tool for Self-Assessment of Cognitive Function in Japan
Aug 28, 2019 09:58 JST
Eisai Co., Ltd. has entered into a business alliance agreement for exclusive development and commercialization of a cognitive function test - Cogstate Brief Battery (CBB) - developed by Cogstate Ltd., in Japan as a digital tool for self-assessment of cognitive function (classified as miscellaneous goods).
More info..

Eisai Provides Tanks to Supply Clean Water to Neglected Tropical Diseases Endemic Regions in Kenya, in Collaboration With Merck
Aug 27, 2019 11:37 JST
Eisai Co., Ltd. announced that it provides tanks to supply clean water for the neglected tropical diseases (NTDs) measuresto the endemic regions in Kenya in collaboration with Merck.
More info..

Eisai to Refresh and Launch Sahne Cream After 20 Years with Mild Scent and New Package
Aug 01, 2019 10:41 JST
Eisai Co., Ltd. announced today that it refresh its SAHNE CREAM (quasi-drug) which has been widely used as medical skin care, for the first time in 20 years, and launch at pharmacies and drug stores in Japan on today August 1, 2019.
More info..

Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Breakthrough Therapy Designation from FDA
Jul 23, 2019 11:37 JST
This is the third Breakthrough Therapy designation for the LENVIMA plus KEYTRUDA combination.
More info..

Eisai Presented Latest Trends of Treatment for Alzheimer's at AAIC 2019
Jul 19, 2019 12:00 JST
Eisai Co.,Ltd. announced the presentation and discussion about the treatment, including oral beta amyloid cleaving enzyme (BACE) inhibitor elenbecestat research data on Alzheimer's disease(AD).
More info..

Eisai Presented Data Showing Quantification of Tau Microtubule Binding Region at AAIC 2019
Jul 19, 2019 08:15 JST
Eisai Co.,Ltd. announced that data relating to a new anti-tau antibody E2814(1) was presented at the Alzheimer's Association International Conference (AAIC) held in Los Angeles, California, United States, from July 14 to 18, 2019 (Poster Presentation No.: P4-696).
More info..

Eisai Presents Research Evaluating Correlation of Highly-Precisely Measured Amyloid Beta in Plasma and Cerebrospinal Fluid with Newly Developed Automated Protein Assay System at AAIC 2019
Jul 18, 2019 13:26 JST
Eisai Co.,Ltd. announced its latest research on evaluation about correlation of amyloid beta (Abeta) in plasma and in cerebrospinal fluid (CSF) by high precision measurement with the newly developed automated protein assay system, jointly developed with Sysmex Corporation.
More info..

Latest Release


More Latest Release >>